Format

Send to

Choose Destination
BMC Pregnancy Childbirth. 2014 Jun 6;14:197. doi: 10.1186/1471-2393-14-197.

The utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy.

Author information

1
Origin Biomarkers, Biocity Scotland, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, UK. dr_sbanerjee@hotmail.com.

Abstract

BACKGROUND:

Previous studies showed that soluble LHCGR/hCG-sLHCGR concentrations in serum or plasma combined with PAPP-A and free βhCG significantly increased the sensitivity of Down's syndrome screen at early pregnancy without altering the false positive rate. The goal of the present study was to further examine the role of sLHCGR forms as combinatorial markers and to investigate whether sLHCGR could serve as an independent biomarker for Down's syndrome in first trimester pregnancy screens.

METHODS:

The PAPP-A, free βhCG, and hCG-sLHCGR concentrations together with nuchal translucency (NT) were measured in 40 Down's and 300 control pregnancies. The sLHCGR concentration was analysed in 40 Down's and 206 control pregnancies.

RESULTS:

The hCG-LHCGR in combination with PAPP-A and free βhCG increased the detection rate (DR) by 35% without altering the false positive rate (FPR). The sLHCGR: hCG-sLHCGR ratio alone detected 80% of Down's pregnancies in first trimester screening, with a false positive rate of 0.5%.

CONCLUSIONS:

While measurement of sLHCGR forms in combination with PAPP-A and free βhCG significantly increases the detection rate of Down's syndrome at first trimester, the ratio of sLHCGR: hCG-sLHCGR acts as an independent marker with a detection rate that is significantly higher than the existing biochemical markers individually for prenatal first trimester screening of Down's syndrome.

PMID:
24906955
PMCID:
PMC4061320
DOI:
10.1186/1471-2393-14-197
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center